Arrowhead Pharmaceuticals, Inc., originally incorporated in South Dakota in 1989, was re-incorporated in Delaware. The company develops drugs to treat intractable diseases by silencing the genes of diseases. Using a wide range of RNA chemical combinations and highly efficient delivery modes, the company's therapies trigger RNA interference mechanisms to induce rapid, deep and persistent knockdown of target genes. There are currently 18 Arrowhead drug candidates in early (Phase 1) to late (Phase 3) clinical trials. 

Expected P&L on Expiry

Key Stats

Pricing Model

About ARWR20260417C65